Obesity Drug Costs: Limited-Time Use, Then Shift To Cheaper Maintenance Floated By Sen. Cassidy

 
• By Sarah Karlin-Smith

Sen. Bill Cassidy and an obesity advocacy group suggest studies test whether obesity patients could be switched to a cheaper maintenance medicine or diet after their initial weight loss on GLP-1s. Approval of Lilly’s Zepbound is a reminder of the expected surge in utilization for the class.

scale food
Sen. Cassidy thinks there should be more to weight loss picture than GLP-1 drugs. • Source: Shutterstock

More from United States

More from North America